SG10201507721SA - CHO-GMT Recombinant Protein Expression - Google Patents

CHO-GMT Recombinant Protein Expression

Info

Publication number
SG10201507721SA
SG10201507721SA SG10201507721SA SG10201507721SA SG10201507721SA SG 10201507721S A SG10201507721S A SG 10201507721SA SG 10201507721S A SG10201507721S A SG 10201507721SA SG 10201507721S A SG10201507721S A SG 10201507721SA SG 10201507721S A SG10201507721S A SG 10201507721SA
Authority
SG
Singapore
Prior art keywords
gmt
cho
protein expression
recombinant protein
recombinant
Prior art date
Application number
SG10201507721SA
Inventor
Song Zhiwei
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG2012004834A external-priority patent/SG192303A1/en
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201507721SA priority Critical patent/SG10201507721SA/en
Publication of SG10201507721SA publication Critical patent/SG10201507721SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001172—Sialyl-Thomson-nouvelle antigen [sTn]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201507721SA 2012-01-20 2013-01-18 CHO-GMT Recombinant Protein Expression SG10201507721SA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201507721SA SG10201507721SA (en) 2012-01-20 2013-01-18 CHO-GMT Recombinant Protein Expression

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2012004834A SG192303A1 (en) 2012-01-20 2012-01-20 Cho-gmt recombinant protein expression
SG2012070652 2012-09-24
SG10201507721SA SG10201507721SA (en) 2012-01-20 2013-01-18 CHO-GMT Recombinant Protein Expression

Publications (1)

Publication Number Publication Date
SG10201507721SA true SG10201507721SA (en) 2015-10-29

Family

ID=54259029

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201404180RA SG11201404180RA (en) 2012-01-20 2013-01-18 Cho-gmt recombinant protein expression
SG10201507721SA SG10201507721SA (en) 2012-01-20 2013-01-18 CHO-GMT Recombinant Protein Expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201404180RA SG11201404180RA (en) 2012-01-20 2013-01-18 Cho-gmt recombinant protein expression

Country Status (6)

Country Link
US (1) US20150119558A1 (en)
EP (1) EP2804946A4 (en)
KR (1) KR20140124789A (en)
CN (1) CN104487570A (en)
SG (2) SG11201404180RA (en)
WO (1) WO2013109190A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
JP6698681B2 (en) 2014-12-01 2020-05-27 アムジエン・インコーポレーテツド Process for manipulating the level of glycan content of glycoproteins
CN108220307B (en) * 2018-01-17 2020-02-21 中国科学院华南植物园 GDP-mannose transport protease and coding gene and application thereof
CN112001329B (en) * 2020-08-26 2021-11-30 深圳太力生物技术有限责任公司 Method and device for predicting protein expression amount, computer device and storage medium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
JP2010505775A (en) * 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Production of cancer-specific immune response against MUC1 and cancer-specific MUC1 antibody
SG184051A1 (en) * 2010-03-25 2012-10-30 Agency Science Tech & Res Method of producing recombinant proteins with mannose- terminated n-glycans

Also Published As

Publication number Publication date
SG11201404180RA (en) 2014-08-28
KR20140124789A (en) 2014-10-27
WO2013109190A3 (en) 2015-01-29
EP2804946A4 (en) 2016-05-25
CN104487570A (en) 2015-04-01
US20150119558A1 (en) 2015-04-30
EP2804946A2 (en) 2014-11-26
WO2013109190A2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
HRP20190454T1 (en) Recombinant factor viii proteins
EP2929045A4 (en) Protein expression enhancing polypeptides
EP2857033A4 (en) Skin-permeating peptide
EP2812347A4 (en) Autophagy-inducing peptide
HK1207120A1 (en) Improved harvest operations for recombinant proteins
HK1209138A1 (en) Peptides
GB201200555D0 (en) Peptide
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
SG11201404180RA (en) Cho-gmt recombinant protein expression
EP3560952C0 (en) Variant of bpifb4 protein
GB201204868D0 (en) Peptides
GB201304973D0 (en) Recombinant protein
GB201223114D0 (en) Novel peptide
HK1201752A1 (en) Alternaria peptides
GB201213672D0 (en) Protein
PT2891663T (en) Psf1-derived peptides
HK1211952A1 (en) Recombinant protein
GB201210286D0 (en) Recombinant polypeptide
GB201215901D0 (en) Protein modification
GB201200743D0 (en) Protein bridges
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201221414D0 (en) Trans-locating peptide
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides